Loading organizations...

§ Private Profile · Menlo Park, CA, USA
Tricida is a technology company.
Tricida is a pharmaceutical company developing and commercializing veverimer (TRC101), an investigational drug. This orally-administered polymer targets metabolic acidosis in chronic kidney disease patients. Veverimer binds and removes hydrochloric acid in the gastrointestinal tract, addressing a condition known to accelerate CKD progression.
Founded August 2013, Tricida was established by a seasoned management team. This team brought extensive experience in therapeutic development and commercialization, particularly in polymers for kidney-related diseases. Their collective insight drove the company's focus on novel treatments for associated metabolic disorders.
The company targets approximately three million US individuals with chronic kidney disease and metabolic acidosis. Tricida’s vision is commercializing veverimer to fulfill a critical unmet medical need. With no FDA-approved chronic therapies existing, the company aims to deliver a foundational treatment, improving patient outcomes.
Tricida has raised $253.0M across 5 funding rounds.
Tricida has raised $253.0M in total across 5 funding rounds.
Tricida, Inc. was a pharmaceutical company developing veverimer (TRC101), a non-absorbed, orally administered polymer to treat metabolic acidosis in patients with chronic kidney disease (CKD).[2][3][4] It targeted a condition affecting millions by binding and removing acid from the gastrointestinal tract, addressing a gap with no FDA-approved chronic therapies at the time.[4] The company served CKD patients and healthcare providers but ceased operations after filing for Chapter 11 bankruptcy liquidation on June 12, 2023.[2]
Note that tricidapharma.com appears to reference a separate, unrelated biotech entity focused on gene therapy and AI-driven research with facilities in the USA and Turkey.[1]
Tricida was founded in August 2013 in South San Francisco, California, by a seasoned management team with extensive experience in therapeutics development, particularly polymers for kidney diseases.[4][6] The idea emerged from expertise in addressing unmet needs in CKD, leading to the discovery and development of veverimer.[4] Early traction included advancing veverimer through Phase III trials, positioning it as a potential first-in-class therapy, though commercialization efforts ultimately failed amid financial challenges culminating in bankruptcy.[2][3]
Tricida lacked broader differentiators like diverse pipelines or tech platforms, contributing to its vulnerability.[2]
Tricida rode the trend of precision therapies for chronic kidney disease, a growing burden amid aging populations and rising diabetes rates, where metabolic acidosis lacked targeted treatments.[4] Timing aligned with heightened pharma interest in nephrology post-2010s, but market forces like regulatory hurdles (e.g., FDA feedback on trials) and funding squeezes for single-asset biotechs worked against it.[2] It highlighted risks in the biotech ecosystem for focused players, influencing investor caution toward late-stage kidney drug developers without diversified pipelines.[2][6]
Tricida's story ended with liquidation in 2023, underscoring biotech perils of trial delays and capital constraints for niche assets like veverimer.[2] No revival is possible post-bankruptcy, but it spotlights enduring CKD needs—trends like AI-accelerated trials and gene therapies (seen in unrelated entities) may reshape the space.[1][4] Its legacy warns of execution risks, tying back to its promise as a kidney-focused innovator that couldn't overcome financial headwinds.
Tricida has raised $253.0M across 5 funding rounds. Most recently, it raised $100.0M Debt in March 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 2, 2018 | $100M Debt Financing | Scott Bluestein | — | Announced |
| Nov 1, 2017 | $58M Series D | — | Atlas Venture, OrbiMed, Cormorant Asset Management, Limulus Venture Partners, Longitude Capital, Sibling Capital Ventures, Venrock, Vivo Capital, Wellington Management | Announced |
| Jul 1, 2016 | $55M Series C | David Hirsch | Atlas Venture, OrbiMed, Limulus Venture Partners, Sibling Capital Ventures, Vivo Capital | Announced |
| Mar 1, 2015 | $30M Series B | OrbiMed | Atlas Venture, Limulus Venture Partners, Sandra Coufal | Announced |
| Sep 1, 2014 | $10M Series A | — | Atlas Venture, OrbiMed | Announced |
Tricida has raised $253.0M in total across 5 funding rounds.
Tricida's investors include Scott Bluestein, Atlas Venture, OrbiMed, Cormorant Asset Management, Limulus Venture Partners, Longitude Capital, Sibling Capital Ventures, Venrock, Vivo Capital, Wellington Management, David Hirsch, Sandra Coufal.